Ser10

Site Information
GAGsAAVsGAGtPVA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 2026017

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 3 , 5 , 6 )
Disease tissue studied:	breast cancer ( 2 ) , breast ductal carcinoma ( 2 ) , cervical cancer ( 6 ) , cervical adenocarcinoma ( 6 ) , leukemia ( 5 ) , acute myelogenous leukemia ( 5 ) , ovarian cancer ( 2 )
Relevant cell line - cell type - tissue:	breast ( 2 ) , HeLa S3 (cervical) ( 6 ) , Jurkat (T lymphocyte) ( 3 ) , KG-1 (myeloid) ( 5 ) , ovary ( 2 )

Upstream Regulation
Treatments:	ischemia ( 2 ) , nocodazole ( 6 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
3	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
4	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
5	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
6	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info